Q-omics provides the consensus-scored RYKP1 profile across patient tissues and cancer cell-line models. RYKP1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RYKP1 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, RYKP1 RNA expression shows 15,444 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where RYKP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RYKP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RYKP1 survival associations across molecular data types. RYKP1 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RYKP1 RNA expression–survival associations across cancer types. High RYKP1 expression shows unfavorable associations in KIRC, PAAD and ACC, but favorable associations in LGG, THCA and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RYKP1 RNA expression.
This table summarizes RYKP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RYKP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RYKP1 shows lower tumor expression in KICH and LUAD and higher tumor expression in COAD, HNSC, BLCA and LIHC. The COAD box plot shows higher RYKP1 RNA expression in tumor versus normal tissue (log2 FC = +0.584, t-test p < 0.001).
This table shows molecular features associated with RYKP1 in patient tissues and cancer cell lines. In patient samples, RYKP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
